Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

NCT06762080 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Metastasis

Interventions

DRUG: Cadonilimab (AK104)
DRUG: Pemetrexed (Alimta)

Sponsor

Guangzhou Medical University